Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
Paul Ehrlich Institut · German Cancer Research Center · +2 more institutions
Abstract
Chimeric antigen receptor (CAR) T cell therapy, together with checkpoint inhibition, has been celebrated as a breakthrough technology due to the substantial benefit observed in clinical trials with patients suffering from relapsed or refractory B-cell malignancies. In this review, we provide a comprehensive overview of the clinical trials performed so far worldwide and analyze parameters such as targeted antigen and indication, CAR molecular design, CAR T cell manufacturing, anti-tumor activities, and related toxicities. More than 200 CAR T cell clinical trials have been initiated so far, most of which aim to treat lymphoma or leukemia patients using CD19-specific CARs. An increasing number of studies address…
Citation impact
- FWCI
- 28.27
- Percentile
- 100%
- References
- 65
Authors
4- JHJessica HartmannCorresponding
Paul Ehrlich Institut
- MSMartina Schüßler‐Lenz
German Cancer Research Center, Deutschen Konsortium für Translationale Krebsforschung, Paul Ehrlich Institut
- ABAttilio Bondanza
IRCCS Ospedale San Raffaele
- CJChristian J. Buchholz
German Cancer Research Center, Deutschen Konsortium für Translationale Krebsforschung, Paul Ehrlich Institut
Topics & keywords
- Chimeric antigen receptor
- Clinical trial
- Medicine
- CAR T-cell therapy
- Lymphoma
- Adverse effect
- Cell therapy
- Immunotherapy